Literature DB >> 24263391

Outcomes of calvarial reconstruction in cancer patients.

Edward I Lee1, Albert H Chao, Roman J Skoracki, Peirong Yu, Franco DeMonte, Matthew M Hanasono.   

Abstract

BACKGROUND: Limited data exist on outcomes of calvarial reconstruction in cancer patients, including the relative efficacy of various cranioplasty materials, and risk factors for complications.
METHODS: A retrospective review was performed of cancer patients who underwent calvarial reconstruction over a 12-year period.
RESULTS: A total of 269 patients underwent 289 calvarial reconstructions. Materials used for cranioplasty included titanium mesh (49.8 percent), methylmethacrylate (16.3 percent), porous polyethylene (4.8 percent), polyetheretherketone (4.5 percent), calcium phosphate cement (3.8 percent), autologous bone grafts (2.1 percent), or a combination of materials (18.3 percent). Perioperative (≤30 days after surgery) complications occurred in 42 cases (14.5 percent), of which 29 (10.0 percent) were at the recipient site, most commonly infection (2.8 percent) and cerebrospinal fluid leak (2.4 percent). Risk factors for perioperative complications included radiation therapy (p = 0.012), prior surgery (p = 0.003), and prior infection (p = 0.014). Late recipient-site complications (>30 days after surgery) occurred in 20 cases (6.9 percent), including infection (3.8 percent) and wound dehiscence (3.1 percent), and for which radiation therapy was identified as a risk factor (p = 0.011). The use of calcium phosphate cement in combination with titanium mesh was associated with a higher long-term complication rate (p < 0.001). Twenty-five cases (8.7 percent) required cranioplasty removal, with infection and dehiscence being risk factors for implant loss (p < 0.001 for both).
CONCLUSIONS: Alloplastic cranioplasty is effective in cancer patients with calvarial defects. Commonly used materials have similar complication profiles, with the possible exception of calcium phosphate cement, which is associated with a higher rate of complications when combined with titanium mesh and used to reconstruct larger defects. CLINICAL QUESTION/LEVEL OF EVIDENCE: Risk, III.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24263391     DOI: 10.1097/01.prs.0000438061.46290.33

Source DB:  PubMed          Journal:  Plast Reconstr Surg        ISSN: 0032-1052            Impact factor:   4.730


  5 in total

1.  Risk factors for surgical site infections and assessment of vancomycin powder as a preventive measure in patients undergoing first-time cranioplasty.

Authors:  Kingsley O Abode-Iyamah; Hsiu-Yin Chiang; Nolan Winslow; Brian Park; Mario Zanaty; Brian J Dlouhy; Oliver E Flouty; Zachary D Rasmussen; Loreen A Herwaldt; Jeremy D Greenlee
Journal:  J Neurosurg       Date:  2017-05-12       Impact factor: 5.115

2.  Reduced CSF leak in complete calvarial reconstructions of microvascular decompression craniectomies using calcium phosphate cement.

Authors:  Chikezie I Eseonu; C Rory Goodwin; Xin Zhou; Debebe Theodros; Matthew T Bender; Dimitrios Mathios; Chetan Bettegowda; Michael Lim
Journal:  J Neurosurg       Date:  2015-07-31       Impact factor: 5.115

3.  Cranioplasty Using a Mixture of Biologic and Nonbiologic Agents.

Authors:  Demetri Arnaoutakis; Arash Bahrami; Jason E Cohn; Jesse E Smith
Journal:  JAMA Facial Plast Surg       Date:  2018-01-01       Impact factor: 4.611

4.  Examining the relationship of immunotherapy and wound complications following flap reconstruction in patients with head and neck cancer.

Authors:  Ashley C Mays; Bharat Yarlagadda; Virginie Achim; Ryan Jackson; Patrik Pipkorn; Andrew T Huang; Karthik Rajasekaran; Shaum Sridharan; Andrew J Rosko; Ryan K Orosco; Andrew M Coughlin; Mark K Wax; Yelizaveta Shnayder; William C Spanos; Donald Gregory Farwell; Lee S McDaniel; Matthew M Hanasono
Journal:  Head Neck       Date:  2021-01-08       Impact factor: 3.147

5.  Anisotropic mineralized collagen scaffolds accelerate osteogenic response in a glycosaminoglycan-dependent fashion.

Authors:  Marley J Dewey; Andrey V Nosatov; Kiran Subedi; Brendan Harley
Journal:  RSC Adv       Date:  2020-04-21       Impact factor: 4.036

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.